** Shares of drug developer Milestone Pharmaceuticals MIST.O fall 8% to 73 cents, extending decline to third day
** Brokerage TD Cowen downgrades MIST to "hold" from "buy", removes PT
** Cites etripamil's regulatory and commercial timing uncertainty
** "The lack of clarity on regulatory timelines puts additional strain on the company's limited capital," says brokerage
** MIST shares fell ~61% on Friday after the U.S. FDA declined to approve its nasal spray, Cardamyst, to treat a type of heart condition
** Including session moves, MIST stock down ~69% YTD compared to ~5% decline in the S&P 500 index .SPX
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.